Data

Poster presentations highlight preclinical data from Ryvu’s PRMT5 program in MTAP-Deficient cancers and its synthetic lethality platform in colorectal cancer modelsVirtual webinar on PRMT5 data and progress to be held on Monday, October 16…

-- In 5 clinical studies involving 968 older men and postmenopausal women with and without muscle wasting, enobosarm has demonstrated the ability to decrease fat mass, increase muscle mass, and improve muscle strength and physical function…

SAN FRANCISCO, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Coalesce.io, the data transformation company, is sponsoring and presenting at 17 cities during the 2023 Snowflake Data Cloud World Tour. The Coalesce team, along with several customers,…

WASHINGTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Virtru, the global leader in data-centric security and privacy, today announced the expansion of its encrypted file-sharing platform, Virtru Secure Share, into Zendesk, with a direct…

TURKU, Finland and BOSTON, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Oy (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pioneering macrophage re-programming for effective cancer immunotherapies,…

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address…

Late-breaking results from Phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitor fenebrutinib in multiple sclerosis (MS) will be presented10-year OCREVUS efficacy and safety data show…

LONDON, Ontario and WINDHAM COUNTY, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced new preclinical data for its…

Data presented at the 2023 Special Meeting on Pancreatic Cancer of the American Association for Cancer Research Preliminary data show local endoscopic injection of NBTXR3 followed by radiotherapy activation remains feasible with a…

Target dose of 12 mg demonstrates robust early activity and manageable tolerability profile:– 63% ORR, 16% cytokine release syndrome (CRS), No ICANS – Phase 1 data set, including recommended Phase 2 dose(s) (RP2D), to be presented by the…